Last $18.73 USD
Change Today -0.05 / -0.27%
Volume 38.9K
LMNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:21 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMNX) Snapshot

Open
$18.71
Previous Close
$18.78
Day High
$18.81
Day Low
$18.55
52 Week High
08/26/13 - $22.30
52 Week Low
04/28/14 - $15.74
Market Cap
801.0M
Average Volume 10 Days
199.6K
EPS TTM
$0.50
Shares Outstanding
42.8M
EX-Date
--
P/E TM
37.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for LUMINEX CORP (LMNX)

Related News

No related news articles were found.

luminex corp (LMNX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMNX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology, which allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling. The company operates in two segments: Technology and Strategic Partnerships (TSP); and Assays and Related Products (ARP). The TSP segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a versatile multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The ARP segment develops and sells assays on xMAP, xTAG, and MultiCode technology for use on its installed base of systems. It provides various assay products that consist of a combination of chemical and biological reagents; and company’s proprietary bead technology used to perform diagnostic and research assays on samples. This segment’s products are focused on the human genetics, personalized medicine, and infectious disease segments of the molecular diagnostic testing market. Luminex Corporation serves pharmaceutical companies, clinical laboratories, and research and medical institutions in the United States, Europe, Asia, Canada, Australia, and internationally. The company has collaboration with Merck & Co. Inc. to develop a companion diagnostic device. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

731 Employees
Last Reported Date: 02/26/14
Founded in 1995

luminex corp (LMNX) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $700.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.5K
Senior Vice President of Operations
Total Annual Compensation: $332.8K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $320.9K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $319.2K
Compensation as of Fiscal Year 2013.

luminex corp (LMNX) Key Developments

Luminex Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Revenue Guidance for the Year 2014

Luminex Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $55,632,000 against $54,287,000 for the same period in the last year. Income from operations was $4,771,000 against $5,041,000 the same period in the last year. Income before income taxes was $4,770,000 against $5,117,000 for the same period in the last year. Net income was $4,725,000 or $0.11 per diluted share against $3,695,000 or $0.09 per diluted share for the same period in the last year. Net cash provided by operating activities was $10,227,000 against net cash used in operating activities of $3,661,000 for the same period in the last year. Purchase of property and equipment was $3,150,000 against $5,431,000 for the same period in the last year. Adjusted income from operations was $9,857,000 against $9,105,000 for the same period in the last year. Adjusted net income was $8,497,000 or $0.20 per diluted share against $7,131,000 or $0.17 per diluted share for the same period in the last year. For the six months, the company reported revenue of $112,193,000 against $107,487,000 for the same period in the last year. Income from operations was $12,956,000 against $3,489,000 the same period in the last year. Income before income taxes was $12,930,000 against $3,530,000 for the same period in the last year. Net income was $10,691,000 or $0.26 per diluted share against $1,184,000 or $0.03 per diluted share for the same period in the last year. Net cash provided by operating activities was $21,664,000 against $6,358,000 for the same period in the last year. Purchase of property and equipment was $6,255,000 against $8,222,000 for the same period in the last year. Adjusted income from operations was $22,336,000 against $18,457,000 for the same period in the last year. Adjusted net income was $18,369,000 or $0.44 per diluted share against $14,989,000 or $0.35 per diluted share for the same period in the last year. The Company reaffirmed its 2014 annual revenue guidance of between $225 and $240 million. The company currently expects its effective tax rate for the year on a GAAP basis to be below 20% and the cash tax component to be less than 50% of book tax expense.

Luminex Corporation to Report Q2, 2014 Results on Jul 28, 2014

Luminex Corporation announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 28, 2014

Luminex Corporation, Q2 2014 Earnings Call, Jul 28, 2014

Luminex Corporation, Q2 2014 Earnings Call, Jul 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $18.73 USD -0.05

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Computer Programs & Systems Inc $60.94 USD -0.62
Fluidigm Corp $27.90 USD -0.04
HealthStream Inc $26.17 USD -0.43
Meridian Bioscience Inc $20.02 USD -0.35
Quidel Corp $23.94 USD -0.22
View Industry Companies
 

Industry Analysis

LMNX

Industry Average

Valuation LMNX Industry Range
Price/Earnings 47.7x
Price/Sales 3.6x
Price/Book 2.7x
Price/Cash Flow 38.9x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit www.luminexcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.